Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00533377 | ACTiF- Assessment of Closed Tibial Fractures | PHASE2 | COMPLETED | 276 | — | — | Jan 1, 2008 | May 1, 2010 | Feb 17, 2012 | 56 | United States, Australia +9 |
| Arm | Type | Description |
|---|---|---|
| CP-533,536 Dose Level 2 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Standard of Care | OTHER | - |
| CP-533,536 Dose Level 1 | EXPERIMENTAL | - |
| CP-533,536 Dose Level 3 | EXPERIMENTAL | - |
| CP-533.536 Dose Level 4 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CP-533, 536 | DRUG | Active study drug |
| Placebo | DRUG | Placebo vehicle |
| Standard of Care | PROCEDURE | Standard surgical procedure |
| CP-533,536 | DRUG | Active study drug |
Inclusion Criteria: * Males or females 17 years or older with confirmed closure of the tibial epiphyses, with a closed fracture of the tibial diaphysis undergoing treatment with reamed locked IM nailing procedure and the absence of an associated compartment syndrome or vascular injury; * Closed tib...